Results 161 to 170 of about 8,577,289 (274)

The Hyers-Ulam-Rassias Stability of ( ð ‘š, ð ‘› ) ( 𠜎, ð œ ) -Derivations on Normed Algebras

, 2012
Ajda Fošner
openalex   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Artificial neural network model of the capacity of diethylenetriamine functionalised zinc oxide-apricot stone shell nanocomposite for sequestering 2,4-dichlorophenoxyacetic acid from wastewater. [PDF]

RSC Adv
Akinola AO, Prabakaran E, Govender K, Pillay K.   +3 more
europepmc   +1 more source

ÐÐÐÐÐÐÐСÐРСÐСТÐÐÐ ÐÐÐ¥ÐСТУ ÐÐФÐРÐÐЦÐÐ ÐÐÐÐÐЬÐÐРСÐÐÐÐÐÐСТÐ

, 2011
Дяченко, Т.О.
openalex   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Structural Fiber Tract Alterations in Relation to Surgery in Children With a Posterior Fossa Tumor. [PDF]

NMR Biomed
Jellema PEJ, Wijnen JP, Kersbergen KJ, Froeling M, Lequin MH, Nieuwenhuis WP, De Luca A, Hoving EW.   +7 more
europepmc   +1 more source

ÐÑоекÑное ÑпÑавление наÑкоемким пÑоизводÑÑвом в неÑÑегазовой пÑомÑÑленноÑÑи (на пÑимеÑе неÑÑадиÑионнÑÑ ÑÑÑдноизвлекаемÑÑ Ð·Ð°Ð¿Ð°Ñов: ÐТРÐÐ)

, 2018
Кирилл Котляров
openalex   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Correction to: Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. [PDF]

Br J Cancer
Dixon KM, Lui GYL, Kovacevic Z, Zhang D, Yao M, Chen Z, Dong Q, Assinder SJ, Richardson DR.   +8 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source